Logotipo do repositório
 

Publicação:
Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia

dc.contributor.authorMaestá, Izildinha [UNESP]
dc.contributor.authorGrowdon, Whitfield B.
dc.contributor.authorGoldstein, Donald P.
dc.contributor.authorBernstein, Marilyn R.
dc.contributor.authorHorowitz, Neil S.
dc.contributor.authorRudge, Marilza Vieira Cunha [UNESP]
dc.contributor.authorBerkowitz, Ross S.
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionMassachusetts General Hospital
dc.contributor.institutionBrigham and Women's Hospital
dc.contributor.institutionDonald P. Goldstein M.D. Tumor Registry
dc.contributor.institutionHarvard Cancer Center
dc.contributor.institutionHarvard Medical School
dc.date.accessioned2014-05-27T11:30:05Z
dc.date.available2014-05-27T11:30:05Z
dc.date.issued2013-08-01
dc.description.abstractObjective The purpose of this study was to identify the clinical factors associated with time to hCG remission among women with low-risk postmolar GTN. Methods This study included a non-concurrent cohort of 328 patients diagnosed with low-risk postmolar GTN according to FIGO 2002 criteria. Associations of time to hCG remission with history of prior mole, molar histology, time to persistence, use of D&C at persistence, presence of metastatic disease, FIGO score, hCG values at persistence, type of first line therapy and use of multiagent chemotherapy were investigated with both univariate and multivariate analyses. Results Overall median time to remission was 46 days. Ten percent of the patients required multi-agent chemotherapy to achieve hCG remission. Multivariate analysis incorporating the variables significant on univariate analysis confirmed that complete molar histology (HR 1.45), metastatic disease (HR 1.66), use of multi-agent therapy (HR 2.00) and FIGO score (HR 1.82) were associated with longer time to remission. There was a linear relationship between FIGO score and time to hCG remission. Each 1-point increment in FIGO score was associated with an average 17-day increase in hCG remission time (95% CI: 12.5-21.6). Conclusions Complete mole histology prior to GTN, presence of metastatic disease, use of multi-agent therapy and higher FIGO score were independent factors associated with longer time to hCG remission in low-risk GTN. Identifying the prognostic factors associated with time to remission and effective counseling may help improve treatment planning and reduce anxiety in patients and their families. © 2013 Elsevier Inc. All rights reserved.en
dc.description.affiliationDepartment of Gynecology and Obstetrics Botucatu Medical School UNESP-Sao Paulo State University, Botucatu, SP
dc.description.affiliationDepartment of Obstetrics and Gynecology Division of Gynecologic Oncology Massachusetts General Hospital, Boston
dc.description.affiliationDepartment of Obstetrics and Gynecology Division of Gynecologic Oncology Brigham and Women's Hospital, Boston
dc.description.affiliationNew England Trophoblastic Disease Center Donald P. Goldstein M.D. Tumor Registry, Boston
dc.description.affiliationTrophoblastic Diseases Center Botucatu Medical School UNESP-Sao Paulo State University, Botucatu, SP
dc.description.affiliationDana Farber Cancer Institute Harvard Cancer Center, Boston
dc.description.affiliationHarvard Medical School, Boston
dc.description.affiliationUnespDepartment of Gynecology and Obstetrics Botucatu Medical School UNESP-Sao Paulo State University, Botucatu, SP
dc.description.affiliationUnespTrophoblastic Diseases Center Botucatu Medical School UNESP-Sao Paulo State University, Botucatu, SP
dc.format.extent312-316
dc.identifierhttp://dx.doi.org/10.1016/j.ygyno.2013.05.017
dc.identifier.citationGynecologic Oncology, v. 130, n. 2, p. 312-316, 2013.
dc.identifier.doi10.1016/j.ygyno.2013.05.017
dc.identifier.issn0090-8258
dc.identifier.issn1095-6859
dc.identifier.lattes9012667997804219
dc.identifier.lattes6758680388835078
dc.identifier.orcid0000-0002-9227-832X
dc.identifier.scopus2-s2.0-84880308422
dc.identifier.urihttp://hdl.handle.net/11449/76144
dc.identifier.wosWOS:000322410900012
dc.language.isoeng
dc.relation.ispartofGynecologic Oncology
dc.relation.ispartofjcr4.540
dc.relation.ispartofsjr2,339
dc.relation.ispartofsjr2,339
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectLow-risk gestational trophoblastic neoplasia hCG remission Prognostic factors Chemotherapy
dc.subjectchorionic gonadotropin
dc.subjectadolescent
dc.subjectadult
dc.subjectcancer chemotherapy
dc.subjectchild
dc.subjectcohort analysis
dc.subjectfemale
dc.subjecthistopathology
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmetastasis
dc.subjectpriority journal
dc.subjectremission
dc.subjectschool child
dc.subjecttrophoblastic tumor
dc.subjectChemotherapy
dc.subjecthCG remission
dc.subjectLow-risk gestational trophoblastic neoplasia
dc.subjectPrognostic factors
dc.subjectAdolescent
dc.subjectAdult
dc.subjectChild
dc.subjectChorionic Gonadotropin
dc.subjectFemale
dc.subjectGestational Trophoblastic Disease
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectPregnancy
dc.subjectPrognosis
dc.subjectRisk
dc.subjectTime Factors
dc.titlePrognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasiaen
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dspace.entity.typePublication
unesp.author.lattes9012667997804219
unesp.author.lattes6758680388835078
unesp.author.orcid0000-0002-9227-832X[6]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentGinecologia e Obstetrícia - FMBpt

Arquivos